• Mashup Score: 2

    Quick Take Video Summary from The New England Journal of Medicine — Mazdutide in Chinese Adults with Obesity or Overweight

    Tweet Tweets with this article
    • GLORY-1 trial: Obesity and overweight are well-recognized risk factors for a range of diseases. Research evaluating the efficacy and safety of mazdutide in long-term weight management is summarized in a short video. https://t.co/8HlufFxpRU https://t.co/eGADYf2wVr

  • Mashup Score: 5

    Malnutrition in older adults is common, underrecognized, and contributes to poor health and risk of death. Guidelines are available to facilitate prevention and treatment of malnutrition.

    Tweet Tweets with this article
    • Malnutrition in Older Adults. https://t.co/9EFtrhCbOB @NEJM @JWatch @NEJMEvidence @NEJMGroup #Geriatrics #GeriOnc #PallOnc https://t.co/FVzTn2y2TO

  • Mashup Score: 41

    Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progr…

    Tweet Tweets with this article
    • Original Article: Nerandomilast in Patients with Progressive Pulmonary Fibrosis (FIBRONEER-ILD phase 3 trial) https://t.co/WLtx356sBv #ATS2025 | @atscommunity https://t.co/Irf3AXfoam

  • Mashup Score: 23

    Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and …

    Tweet Tweets with this article
    • Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: https://t.co/Jhni7W8897 https://t.co/GzSZVWOjih

  • Mashup Score: 0

    A 48-year-old woman presented with a 1-day history of a rash on her right ear that was preceded by 2 days of ear pain and an inability to move the right side of her face.

    Tweet Tweets with this article
    • Image Challenge NEJM: A 48-year-old woman presented with a 1-day history of a rash on her right ear that was preceded by 2 days of ear pain and an inability to move the right side of her face. https://t.co/hEmqv5bdYK https://t.co/FAelwUSu7X

  • Mashup Score: 6

    A 32-year-old woman was brought to the hospital with a 3-year history of progressive weakness of the limbs and trunk. On examination, marked atrophy of the tongue with scalloping and …

    Tweet Tweets with this article
    • Weekend Briefing for June 14, 2025: New Images in Clinical Medicine: Tongue Atrophy and Fasciculations in Motor Neuron Disease https://t.co/dWpvu0GyxS Three New Perspectives: 1️⃣ Medical AI and Clinician Surveillance https://t.co/yirgjDJxJz 2️⃣ Pathobiology — Can We Do https://t.co/fgn1Ln0Wh4

  • Mashup Score: 117

    Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cance…

    Tweet Tweets with this article
    • Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) https://t.co/Zg3IPtTGId #EHA2025 | @EHA_Hematology https://t.co/DlOysGdQGb

  • Mashup Score: 53

    International recommendations advise against the use of intravenous rehydration therapy in children with severe acute malnutrition because of the concern about fluid overload, but evidence to suppo…

    Tweet Tweets with this article
    • Presented at #CCR25: A trial involving children with severe acute malnutrition and gastroenteritis showed no evidence of a difference in mortality at 96 hours between oral and intravenous rehydration strategies. Full GASTROSAM trial results: https://t.co/sbUAoVegCJ https://t.co/vLpnPRwQjG

  • Mashup Score: 117

    Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cance…

    Tweet Tweets with this article
    • Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) https://t.co/Zg3IPtTGId #EHA2025 | @EHA_Hematology https://t.co/DlOysGdQGb